Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Non-Muscle-Invasive and Muscle-Invasive Bladder Cancer — Nursing Symposium Proceedings

Faculty

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of urothelial bladder cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with urothelial bladder cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of the logistical and practical requirements associated with novel therapies for non-muscle-invasive and muscle-invasive bladder cancer in order to educate, counsel and assist patients and their families in decision-making.

At the end of the activity, learners will also be able to

• Understand the biological rationale for combining anti-PD-1/PD-L1 antibodies with bacillus Calmette-Guérin (BCG) for non-muscle-invasive bladder cancer (NMIBC), and discuss available data with and the potential role of this approach.
• Optimize the management of high-risk NMIBC that is unresponsive to BCG, considering the efficacy and tolerability of FDA-endorsed therapies.
• Review available clinical trial evidence with novel intravesical therapies for nonmetastatic bladder cancer, and optimally incorporate these approaches into the care of appropriately selected patients with NMIBC.
• Appreciate the importance of accurately defining platinum eligibility when formulating a care plan for patients with muscle-invasive bladder cancer (MIBC), and recall the criteria that define appropriate versus inappropriate candidates for platinum-based treatment.
• Assess the biological basis for and recently presented research data with combined perioperative anti-PD-1 antibody and antibody-drug conjugate therapy for patients with MIBC and consider the current and potential clinical role of this approach.
• Analyze the scientific justification for perioperative immune checkpoint inhibitor therapy for patients with MIBC, and evaluate available data documenting the efficacy and safety of this strategy.
• Implement a plan to manage the side effects associated with approved therapies for patients with NMIBC and MIBC to support quality of life and continuation of treatment.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of July 1, 2026, to July 1, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/BladderCancer/ILNA.

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS NCPD ACTIVITY
To receive credit for this activity, the participant should review the NCPD information, watch the video and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Emodi and Ms Huober have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Drakaki is on advisory committees with AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; has consulting agreements with AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Pfizer Inc; has contracted research with Acrivon Therapeutics, Adcentrx Therapeutics, Allogene Therapeutics, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Infinity Pharmaceuticals Inc, Kite, A Gilead Company, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Pfizer Inc; is on data and safety monitoring boards/committees for Nektar Therapeutics; is on speakers bureaus for AstraZeneca Pharmaceuticals LP; holds stock OPTIONS — private companies in Athos Therapeutics; and has nonrelevant financial relationships with Dyania Health.

MODERATOR
Dr Friedlander is on advisory committees with Aadi Bioscience, AbbVie Inc, Adaptimmune, Aktis Oncology, Astellas, Bicycle Therapeutics, Bristol Myers Squibb, Gilead Sciences Inc, Merck, Pfizer Inc, Samsung Bioepis; has consulting agreements with Astellas, EMD Serono Inc, Genentech, a member of the Roche Group; and has contracted research with AbbVie Inc, Bicycle Therapeutics, Flare Therapeutics, Genentech, a member of the Roche Group, Johnson & Johnson, Pfizer Inc.

All of the relevant financial relationships above have been mitigated.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Johnson & Johnson, and Merck.

Release date: July 1, 2026
Expiration date: July 1, 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Balar AV et al. Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer – Authors’ reply. Lancet Oncol 2021;22(9):e380. Abstract 

Chen H et al. Ocular adverse events associated with antibody-drug conjugates: A comprehensive pharmacovigilance analysis. Front Immunol 2024;15:1495137. Abstract 

Daetwyler E et al. Corticosteroid-resistant immune-related adverse events: A systematic review. J Immunother Cancer 2024;12(1):e007409. Abstract 

Daneshmand S et al. TAR-200 for bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer: Results from the phase IIb SunRISe-1 study. J Clin Oncol 2025;43(33):3578-88. Abstract 

De Santis M et al. Durvalumab (D) in combination with bacillus Calmette-Guérin (BCG) for BCG-naïve, high-risk non-muscle-invasive bladder cancer (NMIBC): Final analysis of the phase III, open-label, randomised POTOMAC trial. ESMO 2025;Abstract LBA108. 

De Santis M et al. Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): Final analysis of a randomised, open-label, phase 3 trial. Lancet 2025;406(10516):2221-34. Abstract 

Galsky M et al. Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study. Genitourinary Cancers Symposium 2026;Abstract LBA630. 

Jacob JM et al. TAR-200 monotherapy in patients with bacillus Calmette-Guérin–unresponsive high-risk non–muscle-invasive bladder cancer carcinoma in situ: 1-year durability and patient-reported outcomes from SunRISe-1. AUA 2025;Abstract. 

Kopenhafer L et al. Patient experience and unmet needs in high-risk nonmuscle-invasive bladder cancer: Insights from qualitative interviews and a cross-sectional survey. Urol Oncol 2024;42(3):70.e1-10. Abstract 

Li R et al. Bladder-sparing therapy for bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: International Bladder Cancer Group recommendations for optimal sequencing and patient selection. Eur Urol 2024;86(6):516-27. Abstract 

Meeks JJ et al. The first report of disease-free survival analyses from the NIAGARA trial of perioperative durvalumab plus neoadjuvant chemotherapy in muscle-invasive bladder cancer. AUA 2025;Abstract PD39-09. 

Necchi A et al. Pembrolizumab monotherapy for high-risk non-muscle-invasive bladder cancer without carcinoma in situ and unresponsive to BCG (KEYNOTE-057): A single-arm, multicentre, phase 2 trial. Lancet Oncol 2024;25(6):720-30. Abstract 

Powles TB et al. IMvigor011: A phase III trial of circulating tumour (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer. ESMO 2025;Abstract LBA8. 

Powles TB et al. A randomized phase III trial of neoadjuvant durvalumab plus chemotherapy followed by radical cystectomy and adjuvant durvalumab in muscle-invasive bladder cancer (NIAGARA). ESMO 2024;Abstract LBA5. 

Powles TB et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med 2024;390(10):875-88. Abstract 

Powles T et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer. N Engl J Med 2024;391(19):1773-86. Abstract 

Powles TB et al. IMvigor011: A global, double-blind, randomised phase III study of atezolizumab (atezo; anti–PD-L1) vs placebo (pbo) as adjuvant therapy in patients (pts) with high-risk muscle-invasive bladder cancer (MIBC) who are circulating tumour (ct)DNA+ post cystectomy. ESMO 2021;Abstract 716TiP. 

Pradere B et al. Side effect management and procedural best practices with indwelling intravesical drug-releasing systems in the treatment of bladder cancer: recommendations from expert panels. Curr Opin Urol 2026;36(1):123-33. Abstract 

Schneider BJ et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. J Clin Oncol 2021;39(36):4073-126. Abstract 

Shore ND et al. Sasanlimab plus BCG in BCG-naive, high-risk non-muscle invasive bladder cancer: The randomized phase 3 CREST trial. Nat Med 2025;31(8):2806-14. Abstract 

Subiela JD et al. Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy. BJU Int 2026;137(2):270-81. Abstract 

Vilaseca A et al. First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations. AUA 2024;Abstract PD48-02. 

Vulsteke C et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N Engl J Med 2026;394(13):1257-69. Abstract 

Vulsteke C et al. Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: The phase III KEYNOTE-905 study. ESMO 2025;Abstract LBA2. 

Yajima S et al. Enfortumab vedotin with or without pembrolizumab in metastatic urothelial carcinoma: A systematic review and meta-analysis. JAMA Netw Open 2025;8(3):e250250. Abstract